Education
About Us
Working with TipRanks
Follow Us
Harvard Apparatus Regenerative Technology (HRGN)
OTHER OTC:HRGN
HRGN Stock Chart & Stats
$1.82
$0.07(2.66%)
At close: 4:00 PM EST
$1.82
$0.07(2.66%)
Day’s Range― - ―
52-Week Range$0.94 - $2.97
Previous CloseN/A
Volume1.21K
Average Volume (3M)1.13K
Market Cap
$30.77M
Enterprise Value$29.29M
Total Cash (Recent Filing)$1.32M
Total Debt (Recent Filing)$224.00K
Price to Earnings (P/E)―
Beta0.15
Next Earnings
May 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding17,580,744
10 Day Avg. Volume797
30 Day Avg. Volume1,125
Financial Highlights & Ratios
PEG Ratio0.25
Price to Book (P/B)13.68
Price to Sales (P/S)0.00
P/FCF Ratio-9.08
Enterprise Value/Market Cap0.95
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-80.48
Enterprise Value/Ebitda-4.52
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Harvard Apparatus Regenerative Technology News
HRGN FAQ
What was Harvard Apparatus Regenerative Technology’s price range in the past 12 months?
Harvard Apparatus Regenerative Technology lowest stock price was $0.94 and its highest was $2.97 in the past 12 months.
What is Harvard Apparatus Regenerative Technology’s market cap?
Harvard Apparatus Regenerative Technology’s market cap is $30.77M.
When is Harvard Apparatus Regenerative Technology’s upcoming earnings report date?
Harvard Apparatus Regenerative Technology’s upcoming earnings report date is May 18, 2026 which is in 95 days.
How were Harvard Apparatus Regenerative Technology’s earnings last quarter?
Harvard Apparatus Regenerative Technology released its earnings results on Aug 19, 2025. The company reported -$0.114 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.114.
Is Harvard Apparatus Regenerative Technology overvalued?
According to Wall Street analysts Harvard Apparatus Regenerative Technology’s price is currently Overvalued.
Does Harvard Apparatus Regenerative Technology pay dividends?
Harvard Apparatus Regenerative Technology does not currently pay dividends.
What is Harvard Apparatus Regenerative Technology’s EPS estimate?
Harvard Apparatus Regenerative Technology’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Harvard Apparatus Regenerative Technology have?
Harvard Apparatus Regenerative Technology has 17,580,744 shares outstanding.
What happened to Harvard Apparatus Regenerative Technology’s price movement after its last earnings report?
Harvard Apparatus Regenerative Technology reported an EPS of -$0.114 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.885%.
Which hedge fund is a major shareholder of Harvard Apparatus Regenerative Technology?
Currently, no hedge funds are holding shares in HRGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Harvard Apparatus Regenerative Technology
Harvard Apparatus Regenerative Technology Inc., a clinical-stage biotechnology company, focuses on developing regenerative-medicine treatments for disorders of the gastro-intestinal system and other organs resulting from cancer, trauma, or birth defects. Its lead product candidate is Cellspan Esophageal Implant for the treatment of severe esophageal disease. The company's pipeline includes organ-regeneration technology for the repair or replacement of diseased or damaged organs; and product candidates to treat conditions of the esophagus, including traumatic injury, caustic burns, tissue damage following chemoradiation therapy, birth defects, and reconstruction of the colon and uterus wound repair. It also sells consumer health products that focuses on personal healthcare, including dietary supplements. Harvard Apparatus Regenerative Technology Inc. was formerly known as Biostage, Inc. and changed its name to Harvard Apparatus Regenerative Technology Inc. in July 2023. The company was founded in 2009 and is headquartered in Holliston, Massachusetts.
Technical Analysis
Lisata Therapeutics
―
Moleculin Biotech
―
Pulmatrix
―
SAB Biotherapeutics
―
Longeveron
―
Ownership Overview
Options Prices
Currently, No data available
---